Predicting antipsychotic drug response - Replication and extension to six weeks in an international olanzapine study

Schizophrenia Research

Volumn 101, Issue 1-3, 2008, Pages 312-319

  Leucht, Stefan ^a,b   Shamsi, Syed Ali Raza ^a,b   Busch, Raymonde ^c   Kissling, Werner ^a   Kane, John M ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antipsychotic; Prediction; Response; Schizophrenia; Time course

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE;

ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG DOSE INCREASE; DRUG RESPONSE; HUMAN; LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RECEIVER OPERATING CHARACTERISTIC; SCHIZOPHRENIA; SYMPTOM;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HALOPERIDOL; HUMANS; INTERNATIONAL COOPERATION; LOGISTIC MODELS; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; ROC CURVE; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 42749091544     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.01.018     Document Type: Article

References (29)

1. Agid O., Kapur S., Arenovich T., and Zipursky R.B. Delayed-onset hypothesis of antipsychotic action - a hypothesis tested and rejected. Arch. Gen. Psychiatry 60 (2003) 1228-1235
2. Andreasen N., Carpenter W., Kane J., Lasser R., Marder S., and Weinberger D. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 62 (2005) 441-449
3. Bartko G., Herczeg I., and Bekesy M. Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement. J. Clin. Psychiatry 48 (1987) 363-365
4. Bondy B., and Spellman I. Pharmacogenetics of antipsychotics: useful for the clinician?. Curr. Opin. Psychiatry 20 (2007) 126-130
5. Chang Y.C., Lane H.Y., Yang K.H., and Huang C.L. Optimizing early prediction for antipsychotic response in schizophrenia. J. Clin. Psychopharmacol. 26 (2006) 554-559
6. Correll C.U., Malhotra A.K., Kaushik S., McMeniman M., and Kane J.M. Early prediction of antipsychotic response in schizophrenia. Am. J. Psychiatry 160 (2003) 2063-2065
7. Gaebel W., and Awad A.G. Prediction of neuroleptic treatment outcome in schizophrenia. Concepts and methods (1994), Springer Verlag, Wien
8. Hofer A., Hummer M., Huber R., Kurz M., Walch T., and Fleischhacker W.W. Selection bias in clinical trials with antipsychotics. J. Clin. Psychopharmacol. 20 (2000) 699-702
9. Kapur S., Arenovich T., Agid O., Zipursky R., Lindborg S., and Jones B. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am. J. Psychiatry 162 (2005) 939-946
10. Kinon B.J., Liu-Seifert H., Adams D.H., and Citrome L. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia. J. Clin. Psychopharmacol. 26 (2006) 632-637
11. Lane H.Y., Chang Y.C., Chiu C.C., Chen M.L., Hsieh M.H., and Chang W.H. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am. J. Psychiatry 159 (2002) 1593-1595
12. Lane H.Y., Lee C.C., Chang Y.C., Lu C.T., Huang C.H., and Chang W.H. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int. J. Neuropsychopharmacol. 7 (2004) 461-470
13. Lane H.Y., Lin C.C., Huang C.H., Chang Y.C., Hsu S.K., and Chang W.H. Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders. Schizophr. Res. 67 (2004) 63-70
14. Lane H.Y., Lee C.C., Liu Y.C., and Chang W.H. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. Pharmacogenomics 6 (2005) 139-149
15. Lehman A.F., and Steinwachs D.M. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr. Bull. 24 (1998) 1-10
16. Leucht S., Busch R., Hamann J., Kissling W., and Kane J.M. Early onset of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol. Psychiatry 57 (2005) 1543-1549
17. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., and Engel R.R. Clinical implications of BPRS scores. Br. J. Psychiatry 187 (2005) 363-371
18. Leucht S., Kane J.M., Etschel E., Hamann J., Kissling W., and Engel R.R. Linking the PANSS, BPRS and CGI. Clinical implications. Neuropsychopharmacology 31 (2006) 2318-2325
19. Leucht S., Busch R., Kissling W., and Kane J.M. Early prediction of antipsychotic non-response. J. Clin. Psychiatry 68 (2007) 352-360
20. Leucht S., Engel R.R., Bauml J., and Davis J.M. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophr. Bull. 33 (2007) 183-191
21. Lin C.-H., Chou L.-S., Lin C.-H., Hsu C.-Y., Chen Y.-S., and Lane H.-Y. Early prediction of clinical response in schizophrenia patients receiving zotepine. J. Clin. Psychiatry 68 (2007) 1522-1527
22. Nedopil N., Pflieger R., and Ruether E. The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients. Pharmacopsychiatria 16 (1983) 201-205
23. Nicholson I.R., Chapman J.E., and Neufeld R.W.J. Variability in BPRS definitions of positive and negative symptoms. Schizophr. Res. 17 (1995) 177-185
24. Overall J.E., and Gorham D.R. The Brief Psychiatric Rating Scale. Psychol. Rep. 10 (1962) 790-812
25. Riedel M., Strassnig M., Muller N., Zwack P., and Moller H.J. How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials?. Eur. Arch. Psychiatry Clin. Neurosci. 255 (2005) 143-148
26. Stern R.G., Kahn R.S., Harvey P.D., Amin F., Apter S.H., and Hirschowitz J. Early response to haloperidol treatment in chronic schizophrenia. Schizophr. Res. 10 (1993) 165-171
27. Tollefson G.D., Beasley C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., Graffeo K.A., and Thieme M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry 154 (1997) 457-465
28. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 64 (2003) 663-667
29. Zemlan F.P., Thienhaus O.J., and Garver D.L. Length of psychiatric hospitalization and prediction of antipsychotic response. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 14 (1990) 13-24